Список литературы

1. Neufeld E., Muenzer J. The mucopolysaccharidoses//In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Basis of Inherited Disease. 8 ed. New York. NY: McGraw-Hill. 2001. P. 3421 - 52.

2. Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol. 2010; 33(4): 589 - 604. doi: 10.1590/S1415-47572010005000093.

3. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders//JAMA. 1999. V. 281. P. 249 - 54.

4. Khan S.A., Peracha H., Ballhausen D., Wiesbauer A., Rohrbach M., Gautschi M., Mason R.W., Giugliani R., Suzuk Y., Orii K.E., Orii T., Tomatsu S. Epidemiology of mucopolysaccharidoses//Molec. Genet. Metab. 2017. V. 121. P. 227 - 40.

5. Costa-Motta F.M., Bender F., Acosta A., K., Machado T., Bomfim T., Boa Sorte T., da Silva D., Bittles A., Giugliani R., Leistner-Segal S. A community-based study of mucopolysaccharidosis type VI in Brazil: the influence of founder effect, endogamy and consanguinity//Hum Hered. 2014. V. 77. N 1-4. P. 189 - 96.

6. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010; 5: 5. Published 2010 Apr 12. doi: 10.1186/1750-1172-5-5.

7. Giugliani R., Lampe C., Guffon N. et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)-10-year follow-up of patients who previously participated in an MPS VI survey study//American Journal of Medical Genetics, Part A. 2014. V. 164. N 8. P. 1953 - 64.

8. Horovitz D.D.G., T. de S.P.C., Costa A.P. et al. Spinal cord compression in young children with type VI mucopolysaccharidosis//Molecular Genetics and Metabolism. 2011. V. 104. N 3. P. 295 - 300.

9. White K.K., Harmatz P. Orthopedic management of mucopolysaccharide disease//Journal of Pediatric Rehabilitation Medicine. 2010. V. 3. N 1. P. 47 - 56.

10. Williams N, Challoumas D, Eastwood DM. Does orthopaedic surgery improve quality of life and function in patients with mucopolysaccharidoses? J Child Orthop. 2017; 11(4): 289 - 297. doi: 10.1302/1863-2548.11.170042.

11. Мукополисахаридоз VI типа у взрослых/С.В. Моисеев, П.И. Новиков, А.Д. Мешков, В.В. Фомин//Клиническая фармакология и терапия. - 2017. - Т. 26. - N 1. - С. 72 - 79. - EDN ZVLIRR.

12. Golda A., Jurecka A., Tylki-Szymanska A. Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)//International Journal of Cardiology. 2012. V. 158. N 1. P. 6 - 11.

13. Lachman R.S., Burton B.K., Clarke L.A. et al. Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux-Lamy syndrome): Under-recognized and challenging to diagnose//Skeletal Radiology. 2014. V. 43. N 3. P. 359 - 69.

14. Wood T, Bodamer OA, Burin MG, et al. Expert recommendations for the laboratory diagnosis of MPS VI. Mol Genet Metab. 2012; 106(1): 73 - 82. doi: 10.1016/j.ymgme.2012.02.005.

15. Human Gene Mutations Database. Qiagen HGMD Professional

16. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007; 120(2): 405 - 418. doi: 10.1542/peds.2006-2184.

17. Hendriksz CJ, Giugliani R, Harmatz P, et al. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis. 2013; 36(2): 373 - 384. doi: 10.1007/s10545-011-9410-9.

18. Giugliani R., Herber S., Pinto L.L.D.C., Baldo G. Therapy for Mucopolysaccharidosis VI: (Maroteaux-Lamy Syndrome) Present Status and Prospects//Pediatric Endocrinology Reviews: Diabetes Nutrition Metabolism Genetics. 2014. V. 12. Suppl. 1. P. 152 - 58.

19. Brunelli MJ, Atallah , da Silva EM. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. Cochrane Database Syst Rev. 2021; 9(9): CD009806. Published 2021 Sep 17. doi: 10.1002/14651858.CD009806.pub3.

20. Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004; 144(5): 574 - 580. doi: 10.1016/j.jpeds.2004.03.018.

21. Harmatz P, Giugliani R, D Schwartz IV, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008; 94(4): 469 - 475. doi: 10.1016/j.ymgme.2008.04.001.

22. Swiedler SJ, Beck M, Bajbouj M, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A. 2005; 134A(2): 144 - 150. doi: 10.1002/ajmg.a.30579.

23. Brands MM, D, van den Hout JM, et al. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey. J Inherit Metab Dis. 2015; 38(2): 323 - 331. doi: 10.1007/s10545-014-9737-0.

24. Kampmann C, Lampe C, C, et al. Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy. J Inherit Metab Dis. 2014; 37(2): 269 - 276. doi: 10.1007/s10545-013-9649-4.

25. Lampe C, Lampe C, Schwarz M, W, Harmatz P, Mengel E. Craniocervical decompression in patients with mucopolysaccharidosis VI: development of a scoring system to determine indication and outcome of surgery. J Inherit Metab Dis. 2013; 36(6): 1005 - 1013. doi: 10.1007/s10545-013-9591-5.

26. Lampe C, Lampe C, Schwarz M, W, Harmatz P, Mengel E. Craniocervical decompression in patients with mucopolysaccharidosis VI: development of a scoring system to determine indication and outcome of surgery. J Inherit Metab Dis. 2013; 36(6): 1005 - 1013. doi: 10.1007/s10545-013-9591-5.

27. Leal G.N., De Paula A.C., Leone C., Kim C.A. Echocardiographic study of pediatric patients with mucopolysaccharidosis//Cardiology in the Young. 2010. V. 20. N 3. P. 254 - 61.

28. Moreira G.A., Kyosen S.O., Patti C.L., Martins A.M., Tufik S. Prevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference center//Sleep and Breathing. 2014. V. 18. N 4. P. 791 - 97.

29. Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford). 2011; 50 Suppl 5: v49 - v59. doi: 10.1093/rheumatology/ker396.

30. Миронов С.П., Колесов С.В., Переверзев В.С., Колбовский Д.А., Кулешов А.А., Ветрилэ М.С., Казьмин А.И. Опыт хирургического лечения краниовертебрального стеноза у пациентов с мукополисахаридозом I, II, VI типов//Хирургия позвоночника. 2018. Т. 15. N 4. С. 32 - 40.

31. Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int J Clin Pharmacol Ther. 2009; 47 Suppl 1: S100 - S106. doi: 10.5414/cpp47100.

32. Yuen A, Dowling G, Johnstone B, Kornberg A, Coombs C. Carpal tunnel syndrome in children with mucopolysaccaridoses. J Child Neurol. 2007; 22(3): 260 - 263. doi: 10.1177/0883073807300528.

33. Alden TD, Amartino H, Dalla Corte A, Lampe C, Harmatz PR, Vedolin L. Surgical management of neurological manifestations of mucopolysaccharidosis disorders. Mol Genet Metab. 2017; 122S: 41 - 48. doi: 10.1016/j.ymgme.2017.09.011.

34. White, K.K. (2012). Orthopaedic surgery for mucopolysaccharidosis. Current Orthopaedic Practice, 23(5), 394 - 399. doi: 10.1097/bco.0b013e318269c313.

35. Вашакмадзе Н.Д. Мультидисциплинарные принципы ведения детей с мукополисахаридозами в повышении эффективности их диагностики и лечения: автореферат дис. ... доктора медицинских наук: 14.01.08, Екатеринбург, 2019. - 47 с

36. Lin HY, Shih SC, Chuang CK, Chen MR, Niu DM, Lin SP. Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 2013; 8: 71. Published 2013 May 11. doi: 10.1186/1750-1172-8-71.

37. Piraud M, Boyer S, Mathieu M, Maire I. Diagnosis of mucopolysaccharidoses in a clinically selected population by urinary glycosaminoglycan analysis: a study of 2,000 urine samples. Clin Chim Acta. 1993; 221(1-2): 171 - 181. doi: 10.1016/0009-8981(93)90031-x

38. Karageorgos L, Brooks DA, Pollard A, et al. Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat. 2007; 28(9): 897 - 903. doi: 10.1002/humu.20534

39. Мукополисахаридоз VI типа: множественные висцеральные поражения и лечение Наглазимом/А.С. Писарюк, П.В. Лазарев, Т.В. Лобжанидзе, А.А. Шаваров//Клиническая фармакология и терапия. - 2014. - Т. 23. - N 3. - С. 76 - 81. - EDN TCUNFF.

40. Bitencourt FH, Vieira TA, Steiner CE, Neto JC, Boy R, Schwartz IVD. Medical Costs Related to Enzyme Replacement Therapy for Mucopolysaccharidosis Types I, II, and VI in Brazil: A Multicenter Study. Value Health Reg Issues. 2015; 8: 99 - 106. doi: 10.1016/j.vhri.2015.08.002

41. Scarpa M, CM, Amartino H. Epilepsy in mucopolysaccharidosis disorders. Mol Genet Metab. 2017; 122S: 55 - 61. doi: 10.1016/j.ymgme.2017.10.006

42. Rossella Parini, Generoso Andria. Lysosomal Storage Diseases: Early Diagnosis and New Treatments. Mariani Foundation paediatric neurology series, ISSN 0969-0301. John Libbey Eurotext, 2010, pp. 73 - 80

43. Moreira GA, Kyosen SO, Patti CL, Martins AM, Tufik S. Prevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference center. Sleep Breath. 2014; 18(4): 791 - 797. doi: 10.1007/s11325-014-0944-6

44. Ayuna A, Stepien KM, Hendriksz CJ, Balerdi M, Garg A, Woolfson P. Cardiac rhythm abnormalities - An underestimated cardiovascular risk in adult patients with Mucopolysaccharidoses. Mol Genet Metab. 2020; 130(2): 133 - 139. doi: 10.1016/j.ymgme.2020.03.005

45. Mitchell J, Berger KI, Borgo A, et al. Unique medical issues in adult patients with mucopolysaccharidoses. Eur J Intern Med. 2016; 34: 2 - 10. doi: 10.1016/j.ejim.2016.05.017

46. Politei JM, G, Guelbert NB, et al. Recommendations for Evaluation and Management of Pain in Patients With Mucopolysaccharidosis in Latin America. J Pain Symptom Manage. 2018; 56(1): 146 - 152. doi: 10.1016/j.jpainsymman.2018.03.023

47. Рекомендация Коллегии Евразийской экономической комиссии от 13.09.2021 N 23 "О Руководстве по определению возможности использования лекарственной формы лекарственного препарата в педиатрической практике или в отношении отдельной группы педиатрической популяции в целях указания соответствующих сведений в общей характеристике лекарственного препарата и инструкции по медицинскому применению"

48. Приказ Росздравнадзора от 04.05.2021 N 3881 "Об утверждении Ведомственной программы профилактики нарушений обязательных требований при осуществлении государственного контроля качества и безопасности медицинской деятельности, федерального государственного надзора в сфере обращения лекарственных средств и государственного контроля за обращением медицинских изделий"

49. "МУ 3.3.2.2437-09. 3.3.2. Медицинские иммунобиологические препараты. Применение термоиндикаторов для контроля температурного режима хранения и транспортирования медицинских иммунобиологических препаратов в системе "холодовой цепи". Методические указания" (утв. Главным государственным санитарным врачом РФ 21.01.2009).

50. Pilz H, von Figura K, Goebel HH. Deficiency of arylsulfatase B in 2 brothers aged 40 and 38 years (Maroteaux-Lamy syndrome, type B). Ann Neurol. 1979; 6(4): 315 - 325. doi: 10.1002/ana.410060405

51. Mendes, C.S.C., et al. "Epileptic seizures profile in patients with mucopolysaccharidosis (MPS) types I, II and VI." J. Inherit. Metab. Dis 39 (2016): S192.

52. Akyol MU, Alden TD, Amartino H, et al. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019; 14(1): 118. Published 2019 May 29. doi: 10.1186/s13023-019-1080-y

53. T, Gregersen HN, F. Normal MPS excretion, but dermatan sulphaturia, combined with a mild Maroteaux-Lamy phenotype. J Med Genet. 1991; 28(7): 499 - 501. doi: 10.1136/jmg.28.7.499